Weekly RSV Vaccination Dashboard

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 60─74 years with high-risk conditions for RSV are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Data and charts are available here.

As of November 9, 2024, among adults ≥75 years:

• An estimated 39.7% (95% Confidence Interval: 37.7%─41.6%) reported having ever received an RSV vaccine.
  • An additional 7.2% (4.2%─10.3%) reported they definitely will get a vaccine,
    
• Vaccination coverage varied by disability status, health insurance status, poverty status, race and ethnicity, urbanicity, and presence of a chronic medical condition.
• Additional RSV vaccination data by demographic characteristics at the national and regional level are available.

As of November 9, 2024, among adults 60─74 years with a high-risk condition for RSV:

• An estimated 31.6% (28.1%─35.0%) reported having ever received an RSV vaccine.
  • An additional 15.9% (11.6%─20.3%) reported they definitely will get a vaccine.
• Vaccination coverage varied by disability status, health insurance status, poverty status, and race and ethnicity.
• Additional RSV vaccination data by demographic characteristics at the national and regional level are available.

Adults 75+ RSV Vaccination Administration and Coverage

RSV vaccination coverage estimates among adults 75 years and older as of the end of October 2024 based on IIS data submitted to CDC by 30 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.

• Among the currently reporting 28 state and city IIS jurisdictions, RSV vaccination coverage among adults 75 years and older ranged from 1.4% to 41.0%. Among 2 U.S. territorial and affiliated island jurisdictions, coverage ranged from 2.2% to 2.7%.

Adults 75+ RSV Vaccinations Administered

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 75 years and older, based on healthcare claims data. Data and charts are available here.

• During August 12, 2023, through October 26, 2024, among adults ≥75 years:
  • An estimated ~5.30 million doses of RSV vaccine were administered in retail pharmacies. Of these, an estimated 805,542 doses were administered since August 4, 2024.
  • An estimated 106,905 doses of RSV vaccine were administered in physicians’ medical offices. Of these, an estimated 16,565 doses were administered since August 4, 2024.

Pregnant Persons RSV Vaccination Coverage

Estimates of RSV vaccination coverage for pregnant persons 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available here.

• As of November 9, 2024, among persons who were pregnant and at least 32 weeks gestation since September 1, 2024, overall coverage with the RSV vaccine was 31.9%.
• Vaccination coverage was highest among non-Hispanic Asian (44.3%) pregnant persons and lowest among non-Hispanic Black (21.2%) pregnant persons.

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females age 18─49 years with infants <8 months during the RSV season (born since April 1, 2024) are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. Data and charts are available here.

• As of September 2024, among females with an infant born since April 1, 52.7% reported that they would definitely get nirsevimab for their infant.

Monthly Jurisdiction Nirsevimab Administration and Coverage for Infants

Nirsevimab administration and coverage estimates among infants <8 months (born since April 1, 2024) as of the end of October 2024 based on IIS data submitted to CDC by 30 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.

• Among the currently reporting 28 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months (born since April 1) ranged from 0.1% to 33.2%. Among 2 U.S. territorial and affiliated island jurisdictions, coverage ranged from 0.1% to 9.8%.